Updates in the Management of Myeloproliferative Neoplasms

EP. 1: Characterization of Myeloproliferative Neoplasms

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 2: Polycythemia Vera: Diagnostic Work-up

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 3: Polycythemia Vera: Bone Marrow Biopsies

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 4: Polycythemia Vera: Prognostic Markers

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 5: Polycythemia Vera: Risk Assessment

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 6: Polycythemia Vera: Monitoring Patients

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 7: Management of Low-Risk Polycythemia Vera

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 8: Treatment Options for High-Risk Polycythemia Vera

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 9: Polycythemia Vera: Switching Therapy

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 10: Polycythemia Vera: Ruxolitinib Trial Data

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 11: Utilization of Ruxolitinib for Polycythemia Vera

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 12: Polycythemia Vera: PROUD-PV Trial

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 13: Primary Myelofibrosis: Risk Stratification

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 14: Management of Low-Risk Primary Myelofibrosis

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 15: Treating Intermediate/High-Risk Primary Myelofibrosis

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 16: Ruxolitinib for Primary Myelofibrosis

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 17: Ruxolitinib and Surgical Interventions

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 18: Fedratinib for Primary Myelofibrosis

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 19: JAK2 Inhibitor Selection for Primary Myelofibrosis

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 20: Primary Myelofibrosis: Trials of Interest

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 21: Classifying Patients With Essential Thrombocythemia

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 22: Essential Thrombocythemia: Treatment Optimization

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

EP. 23: Advances in the Management of MPNs

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Episodes

EP. 1: Characterization of Myeloproliferative Neoplasms

EP. 2: Polycythemia Vera: Diagnostic Work-up

EP. 3: Polycythemia Vera: Bone Marrow Biopsies

EP. 4: Polycythemia Vera: Prognostic Markers

EP. 5: Polycythemia Vera: Risk Assessment

EP. 6: Polycythemia Vera: Monitoring Patients

EP. 7: Management of Low-Risk Polycythemia Vera

EP. 8: Treatment Options for High-Risk Polycythemia Vera

EP. 9: Polycythemia Vera: Switching Therapy

EP. 10: Polycythemia Vera: Ruxolitinib Trial Data

EP. 11: Utilization of Ruxolitinib for Polycythemia Vera

EP. 12: Polycythemia Vera: PROUD-PV Trial

EP. 13: Primary Myelofibrosis: Risk Stratification

EP. 14: Management of Low-Risk Primary Myelofibrosis

EP. 15: Treating Intermediate/High-Risk Primary Myelofibrosis

EP. 16: Ruxolitinib for Primary Myelofibrosis

EP. 17: Ruxolitinib and Surgical Interventions

EP. 18: Fedratinib for Primary Myelofibrosis

EP. 19: JAK2 Inhibitor Selection for Primary Myelofibrosis

EP. 20: Primary Myelofibrosis: Trials of Interest

EP. 21: Classifying Patients With Essential Thrombocythemia

EP. 22: Essential Thrombocythemia: Treatment Optimization

EP. 23: Advances in the Management of MPNs

Trending on OncLive

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma